At #EAU25, Dr. Giulio Francolini and colleagues presented early results from the ongoing PERSIAN trial (NCT03449719) a randomized phase II study investigating the addition of stereotactic body radiotherapy (SBRT) to apalutamide + ADT in patients with oligometastatic hormone-sensitive prostate cancer (mHSPC).
Among the first 87 patients with three months of follow-up, complete biochemical response (PSA <0.2 ng/ml) was observed in 91.1% of patients receiving systemic therapy alone and 92.9% in those also receiving SBRT. Although not statistically significant overall, a significant benefit was noted in patients with fewer than three metastatic sites (OR 5.88; p = 0.03).
These early results highlight a potential role for SBRT in carefully selected patients with low-volume mHSPC. Full enrollment is expected by the end of 2024, with additional data anticipated in 2025.
For more details: https://lnkd.in/dVnjZG3e
